

OMTO, Volume 6

Supplemental Information

Chemovirotherapy of Pancreatic Adenocarcinoma

by Combining Oncolytic Vaccinia Virus

GLV-1h68 with *nab*-Paclitaxel Plus Gemcitabine

Eike Binz, Susanne Berchtold, Julia Beil, Martina Schell, Christine Geisler, Irina Smirnow, and Ulrich M. Lauer




Figure S1: Schedules of the chemovirotherapeutic combination settings of GLV-1h68 with either nab-paclitaxel or gemcitabine. Tumor cells were infected with GLV-1h68 followed by a medium change at 1 hpi. **(a)** Setting of chemotherapy initiated “early” at 1 hpi. **(b)** Setting of chemotherapy started “late” at 24 hpi. Accordingly, change of the culture medium and addition of the respective chemotherapeutic compound (nab-paclitaxel or gemcitabine) was performed either “early” (at 1 hpi) or “late” (at 24 hpi). Remaining tumor cell masses were analyzed at 72 hpi by Sulforhodamine B (SRB) assays. hpi: hour(s) post infection.